In light of Incyte's epacadostat debacle, NewLink scraps PhIII plans for its own IDO drug
After seeing its shares get dragged down by Incyte’s late-stage debacle, NewLink Genetics is scrapping a PhIII trial for its own IDO drug, raising …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
